TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years

This multicenter prospective study conducted through the Institute of Hematology & Blood Diseases Hospital in China is looking to recruit 100 ITP patients at least 14 years of age or older to see how well the use of a thrombopoetin-receptor agonist (TPO-RA) is in treating ITP after failure to first-line therapies. The TPO-RAs used in this study include eltrombopag (Promacta/Revolade), Herombopag (Hengqu), and Avatrombopag (Doptelet). Recruitment criteria also includes having a diagnosis of primary ITP with two back-to-back platelet counts less than 30,000 µL or having two bleeding events less than seven days apart. Exclusion criteria includes previous use of TPO-RAs for a maximum of four weeks or two weeks with no response (defined as not achieving a platelet count higher than 30,000 after treatment or having bleeding with little change from baseline platelet count.


Status: Recruiting

back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo